CHLORTHALIDONE; RESERPINE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for chlorthalidone; reserpine and what is the scope of patent protection?
Chlorthalidone; reserpine
is the generic ingredient in two branded drugs marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for CHLORTHALIDONE; RESERPINE
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 3 |
| DailyMed Link: | CHLORTHALIDONE; RESERPINE at DailyMed |
Recent Clinical Trials for CHLORTHALIDONE; RESERPINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| VA Office of Research and Development | |
| US Department of Veterans Affairs | |
| National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for CHLORTHALIDONE; RESERPINE
US Patents and Regulatory Information for CHLORTHALIDONE; RESERPINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | REGROTON | chlorthalidone; reserpine | TABLET;ORAL | 015103-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | DEMI-REGROTON | chlorthalidone; reserpine | TABLET;ORAL | 015103-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
